⠀
• Novo will present new real-world data on Wegovy pill, including weight outcomes, treatment switching and patient-reported results.
• CagriSema presentations will cover appetite regulation, food-cue brain responses, body composition and bone remodeling; zenagamtide Phase 2b data in type 2 diabetes will also be shown.
• Additional data span Wegovy 7.2 mg, Ozempic 2.0 mg, cardio-renal outcomes and comparisons with tirzepatide.